A Multicenter Study Evaluating the Discontinuation of Eculizumab Therapy in Children with Atypical Hemolytic Uremic Syndrome

Background: Atypical hemolytic uremic syndrome (aHUS) is a rare, life-threatening thrombotic microangiopathy (TMA), which has been treated successfully with eculizumab. The optimal duration of eculizumab in treating patients with aHUS remains poorly defined. Methods: We conducted a multicenter retro...

Полное описание

Библиографические подробности

Главные авторы:	Saeed AlZabali, Sawsan AlBatati, Khawla Rahim, Hassan Faqeehi, Abubaker Osman, Abdulaziz Bamhraz, Mohammed A. Saleh, Jameela A. Kari, Majed Aloufi, Loai Eid, Haydar Nasser, Abubakr Imam, Entesar AlHammadi, Omar Alkandari, Mohammed Al Riyami, Sidharth Sethi, Christoph Licht, Khalid A. Alhasan, Abdulkarim AlAnazi
Формат:	Artigo
Язык:	Inglês
Опубликовано:	MDPI AG 2022-11-01
Серии:	Children
Предметы:	atypical hemolytic uremic syndrome discontinuation of eculizumab thrombotic microangiopathy HUS relapse
Online-ссылка:	https://www.mdpi.com/2227-9067/9/11/1734
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!